Parkinson's disease
Conditions
Interventions
Experimental group:An infusion of dexmedetomidine
Control group:None
Sponsors
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.In line with the PD diagnostic criteria of Parkinson's Disease in China (2016 edition); 2.Aged 35 to 75 years and no sex restriction; 3.ASA: grade II-III; 4.Body mass index is 18.5-30kg/m^2; 5.Able to complete scale examination; 6.Agree with the researcher.
Exclusion criteria
Exclusion criteria: 1.Severe organ insufficiency; 2.Combined with brain functional diseases other than Parkinson's disease. 3.Allergic to dexmedetomidine; 4.Hearing impairment, unable to cooperate with wake-up test; 5.Patients with bradyarrhythmia; 6.Severe hypertension; 7.Severe cognitive or mental disorders, difficult to cooperate with the trial; 8.Parkinson's superposition syndrome, multisystem atrophy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The dosage used for dexmedetomidine;The time between falling asleep and opening the eyes on the breath of a sleeping patient; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood pressure, heart rate, pulse oxygen saturation and brain dual frequency index;Recovery quality; | — |
Countries
China
Contacts
Public ContactKang Fang
The First Affiliated Hospital of University of Science and Technology of China (Southern District Phase 2)
Outcome results
None listed